TKIs vs ADCs: Treatment Sequencing Considerations in HER2-Mutant NSCLC

Martin F. Dietrich, MD, PhD, and Ticiana Leal, MD, examine sequencing considerations between tyrosine kinase inhibitors and antibody-drug conjugates in HER2-mutant non–small cell lung cancer. Dietrich discusses the relative efficacy and toxicity profiles of these classes and how they may influence treatment selection. Leal emphasizes the importance of disease characteristics, including CNS involvement and treatment goals, when determining optimal sequencing strategies.